Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Shares of US biotech firm ACADIA Pharmaceuticals plunged 22% to 34.70 in after-hours trading, after it announced that it now plans to submit a New Drug application for Nuplazid (pimavanserin) for the treatment of Parkinson’s disease in the second half of 2015. 12 March 2015
Pharma industry sales force levels in 2014 showed a slowdown in the decline seen in previous years, according to market research company Cegedim Strategic Data (CSD). 5 March 2015
Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease, has appointed Rafael Amado as chief medical officer and Adrian Rawcliffe as chief financial officer. 4 March 2015
Japan’s largest drugmaker Takeda Pharmaceutical has promoted Christophe Weber from representative director, president and chief operating officer to representative director, president and chief executive officer. 4 March 2015
German family-owned drug major Boehringer Ingelheim has been in the biosimilars business since the end of 2011, when it developed what was effectively a startup within the company to manufacture a new kind of therapy. What it now has in 2015 is a portfolio of biosimilar products, three of which are in Phase III. 2 March 2015
Jeffrey Barrett has been appointed the founding director for the Centre for Therapeutic Target Validation, a public-private partnership between GlaxoSmithKline, the European Bioinformatics Institute and the Wellcome Trust Sanger Institute. 2 March 2015
The former chief executive of French pharma major Sanofi Christopher Viehbacher has been appointed to the board of directors of US R&D company PureTech. 27 February 2015
Japanese drug major Astellas Pharma is to make organizational and personnel changes in the Americas, as well as streamlining business development globally. 20 February 2015
Confirming what the media had been saying most of the week, French pharma major Sanofi late yesterday said that Olivier Brandicourt will become the firm’s chief executive, effective April 2. 20 February 2015
Kymab, a pharma company based in Cambridge, UK, focusing on monoclonal antibodies, has appointed Anne Hyland as chief financial officer. 19 February 2015